Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Therapeutic Use
- 26 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2016 Status changed from active, no longer recruiting to recruiting.